동향
Home > DB > 동향
| A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. | |||
|---|---|---|---|
| 분류 | pharmacokinetics | 조회 | 1379 |
| 발행년도 | 2015 | 등록일 | 2015-09-24 |
| 출처 | Future Oncol (바로가기) | ||
|
Aims: To evaluate the safety and maximum tolerated dose (MTD) of afatinib combined with nintedanib.
MATERIALS & METHODS:
Patients received afatinib 10-20 mg daily plus nintedanib 150-200 mg twice daily (28-day cycle). Dose escalation followed a 3+3 design.
(후략)
|
|||
|
|
이전글
다음글